|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.53 USD | -0.22% |
|
-3.00% | -33.09% |
| Apr. 12 | Uniqure N.V. Announces Paula Soteropoulos Will Not Stand for Re-Election as Non-Executive Director | CI |
| Apr. 02 | UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating | MT |
Oct 5 (Reuters) - Dutch gene therapy maker uniQure N.V said on Thursday it will reduce about 20% of total workforce and discontinue investments in more than half of its research and technology projects as part of a restructuring plan to save costs.
The restructuring, however, will not affect the manufacturing of multi-million-dollar gene therapy Hemgenix for CSL Behring, the company said.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sherry Jacob-Phillips)
| 1st Jan change | Capi. | |
|---|---|---|
| -33.09% | 220M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
UNIQURE N.V. 
